BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1264 related articles for article (PubMed ID: 15289847)

  • 1. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
    Caldés T; Godino J; Sanchez A; Corbacho C; De la Hoya M; Lopez Asenjo J; Saez C; Sanz J; Benito M; Ramon Y Cajal S; Diaz-Rubio E
    Oncol Rep; 2004 Sep; 12(3):621-9. PubMed ID: 15289847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microsatellite instability analysis and/or immunostaining for the diagnosis of hereditary nonpolyposis colorectal cancer?
    Halvarsson B; Lindblom A; Rambech E; Lagerstedt K; Nilbert M
    Virchows Arch; 2004 Feb; 444(2):135-41. PubMed ID: 14652751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms.
    Shia J; Klimstra DS; Nafa K; Offit K; Guillem JG; Markowitz AJ; Gerald WL; Ellis NA
    Am J Surg Pathol; 2005 Jan; 29(1):96-104. PubMed ID: 15613860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers.
    Lawes DA; Pearson T; Sengupta S; Boulos PB
    Br J Cancer; 2005 Aug; 93(4):472-7. PubMed ID: 16106253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
    Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
    Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium.
    Plaschke J; Engel C; Krüger S; Holinski-Feder E; Pagenstecher C; Mangold E; Moeslein G; Schulmann K; Gebert J; von Knebel Doeberitz M; Rüschoff J; Loeffler M; Schackert HK
    J Clin Oncol; 2004 Nov; 22(22):4486-94. PubMed ID: 15483016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
    Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
    Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer.
    Niessen RC; Berends MJ; Wu Y; Sijmons RH; Hollema H; Ligtenberg MJ; de Walle HE; de Vries EG; Karrenbeld A; Buys CH; van der Zee AG; Hofstra RM; Kleibeuker JH
    Gut; 2006 Dec; 55(12):1781-8. PubMed ID: 16636019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis.
    Berends MJ; Wu Y; Sijmons RH; van der Sluis T; Ek WB; Ligtenberg MJ; Arts NJ; ten Hoor KA; Kleibeuker JH; de Vries EG; Mourits MJ; Hollema H; Buys CH; Hofstra RM; van der Zee AG
    J Clin Oncol; 2003 Dec; 21(23):4364-70. PubMed ID: 14645426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.
    Piñol V; Castells A; Andreu M; Castellví-Bel S; Alenda C; Llor X; Xicola RM; Rodríguez-Moranta F; Payá A; Jover R; Bessa X;
    JAMA; 2005 Apr; 293(16):1986-94. PubMed ID: 15855432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of mismatch repair gene germline mutation carrier among Chinese population with colorectal cancer.
    Jin HY; Liu X; Li VK; Ding Y; Yang B; Geng J; Lai R; Ding S; Ni M; Zhao R
    BMC Cancer; 2008 Feb; 8():44. PubMed ID: 18257912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The first molecular analysis of a Hungarian HNPCC family: a novel MSH2 germline mutation].
    Czakó L; Tiszlavicz L; Takács R; Baradnay G; Lonovics J; Cserni G; Závodná K; Bartosova Z
    Orv Hetil; 2005 May; 146(20):1009-16. PubMed ID: 15945244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic rearrangements in MSH2, MLH1 or MSH6 are rare in HNPCC patients carrying point mutations.
    Pistorius S; Görgens H; Plaschke J; Hoehl R; Krüger S; Engel C; Saeger HD; Schackert HK
    Cancer Lett; 2007 Apr; 248(1):89-95. PubMed ID: 16837128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HNPCC: six new pathogenic mutations.
    Kunstmann E; Vieland J; Brasch FE; Hahn SA; Epplen JT; Schulmann K; Schmiegel W
    BMC Med Genet; 2004 Jun; 5():16. PubMed ID: 15217520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations.
    Wu Y; Berends MJ; Mensink RG; Kempinga C; Sijmons RH; van Der Zee AG; Hollema H; Kleibeuker JH; Buys CH; Hofstra RM
    Am J Hum Genet; 1999 Nov; 65(5):1291-8. PubMed ID: 10521294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low levels of microsatellite instability characterize MLH1 and MSH2 HNPCC carriers before tumor diagnosis.
    Alazzouzi H; Domingo E; González S; Blanco I; Armengol M; Espín E; Plaja A; Schwartz S; Capella G; Schwartz S
    Hum Mol Genet; 2005 Jan; 14(2):235-9. PubMed ID: 15563510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
    Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
    J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation.
    Gill S; Lindor NM; Burgart LJ; Smalley R; Leontovich O; French AJ; Goldberg RM; Sargent DJ; Jass JR; Hopper JL; Jenkins MA; Young J; Barker MA; Walsh MD; Ruszkiewicz AR; Thibodeau SN
    Clin Cancer Res; 2005 Sep; 11(18):6466-71. PubMed ID: 16166421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining.
    Mangold E; Pagenstecher C; Friedl W; Fischer HP; Merkelbach-Bruse S; Ohlendorf M; Friedrichs N; Aretz S; Buettner R; Propping P; Mathiak M
    J Pathol; 2005 Dec; 207(4):385-95. PubMed ID: 16216036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered expression of MLH1, MSH2, and MSH6 in predisposition to hereditary nonpolyposis colorectal cancer.
    Renkonen E; Zhang Y; Lohi H; Salovaara R; Abdel-Rahman WM; Nilbert M; Aittomaki K; Jarvinen HJ; Mecklin JP; Lindblom A; Peltomaki P
    J Clin Oncol; 2003 Oct; 21(19):3629-37. PubMed ID: 14512394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.